PREDICTION OF POTENTIAL INHIBITORS SIMILAR TO REMDESIVIR (GS-5734) AGAINST 7BTF SARS COV 2 RNA DEPENDENT RNA POLYMERASE – AN IN-SILICO APPROACH

The novel Corona Virus Disease – 19 (COVID-19) is a Contagious disease spreading among Animals and Humans, a Severe Acute Respiratory Syndrome CoronaVirus-2 (SARS CoV2). The First case was identified in Wuhan, China as the disease has unfolded worldwide to the continuing pandemic. It created more infected cases and deaths worldwide, creating an urge for newer drugs of manipulate the Ongoing Pandemic and address the contemporary state of affairs. Remdesivir (GS-5734) has been recognized because the first authorized remedy for intense COVID-19 and has also been recognized to be a novel nucleoside an a log with a large antiviral activity spectrum among RNA viruses which include ebolavirus (EBOV) and the respiratory pathogens Middle East breathing syndrome coronavirus (MERS-CoV), SARS-CoV and SARS-CoV-2. Being first defined in 2016, the drug was derived from an Antiviral library of small molecules intended to target emerging pathogenic RNA viruses. Remdesivir has been discovered to lessen the time to restoration of hospitalized patients who require supplemental oxygen and has a high-quality effect on mortality results whilst having a positive safety profile. 7BTF-SARS-CoV-2, an RNA-structured RNA polymerase, has been discovered as an ability goal gambling a vital role within the viral lifecycle. This study aims at developing an inhibitor using Virtual screening of Compounds similar to Remdesivir (GS-5734). Molecular Docking studies have been performed, and quantitative structure-activity relationship (QSAR) studies have been performed in opposition to compounds similar to Remdesivir. Their inhibitory activity was studied and justified for structurally similar compounds.